Osteogenesis Imperfecta (Child)

1. Overview

Osteogenesis Imperfecta (OI) is a heritable connective tissue disorder characterised by bone fragility, resulting from quantitative or qualitative defects in type I collagen. First described by Ekman in 1788 and extensively classified by Sillence in 1979, OI represents a clinically and genetically heterogeneous group of conditions unified by their tendency to fracture with minimal trauma. [1,2]

The hallmark of OI is skeletal fragility leading to recurrent fractures, which may occur in utero, during the neonatal period, or throughout childhood and adolescence. The clinical spectrum ranges from perinatal lethal forms (Type II) to mild variants compatible with normal life expectancy and near-normal function (Type I). Beyond skeletal manifestations, OI affects multiple organ systems due to the ubiquitous distribution of type I collagen in connective tissues. [3]

Early recognition and appropriate multidisciplinary management are critical. Modern therapeutic approaches, particularly intravenous bisphosphonate therapy and evolving surgical techniques such as telescoping intramedullary rodding, have substantially improved outcomes. Quality of life for children with OI has transformed over the past three decades, with many individuals achieving functional independence and participation in education, employment, and family life. [4,5]

---

2. Epidemiology

Incidence and Prevalence

Osteogenesis Imperfecta affects all ethnic groups and occurs worldwide without significant geographic or racial predilection. [6]

Demographic Distribution

• Sex: Equal male-to-female ratio across all types [1]
• Age at diagnosis:
  • "Type I: Often infancy/early childhood (first fracture)"
  • "Type II: Prenatal (ultrasound) or perinatal"
  • "Type III: Prenatal, perinatal, or infancy"
  • "Type IV: Infancy to early childhood"
• Family history: Present in ~60% of Type I; most Type II cases are de novo mutations [8]

Risk Factors

• Parental age: Advanced parental age associated with de novo mutations [9]
• Family history: Autosomal dominant inheritance pattern in most cases
• Consanguinity: Increased risk for rare autosomal recessive forms

---

3. Aetiology & Pathophysiology

Genetic Basis

The molecular pathology of OI centres on defects in type I collagen, the most abundant protein in bone, accounting for approximately 90% of the organic matrix. [10]

Classical Forms (85–90% of cases)

Type I collagen structure: Triple helix composed of two α1(I) chains and one α2(I) chain. Mutations disrupt synthesis, structure, or post-translational modification. [11]

Mutation Types and Consequences

1. Null alleles (COL1A1 haploinsufficiency):

   • Result in 50% reduction in normal collagen production
   • Generally milder phenotype (Type I OI)
   • Bone structure qualitatively normal but quantitatively deficient

2. Structural mutations (glycine substitutions):

   • Disrupt the Gly-X-Y triple helix repeat
   • Dominant-negative effect on collagen assembly
   • Severe phenotypes (Types II, III, IV)
   • Position of mutation correlates with severity [12]

Rare Forms (10–15% of cases)

Over 20 additional genes implicated in OI pathogenesis, affecting: [13]

• Collagen post-translational modification (e.g., CRTAP, LEPRE1, PPIB)
• Collagen folding and trafficking (e.g., SERPINH1, FKBP10)
• Osteoblast differentiation (e.g., SP7, WNT1)
• Bone mineralisation (e.g., IFITM5, SERPINF1)

Most rare forms show autosomal recessive inheritance. [14]

Exam Detail: ### Molecular Pathophysiology

Collagen Biosynthesis Pathway:

1. Transcription: COL1A1 and COL1A2 genes transcribed to pro-α chains
2. Translation: Rough endoplasmic reticulum synthesises pro-α chains
3. Hydroxylation: Prolyl and lysyl hydroxylases modify proline and lysine residues (requires vitamin C)
4. Glycosylation: Addition of glucose and galactose to hydroxylysine
5. Triple helix formation: Two α1(I) and one α2(I) chains associate via C-terminal propeptides
6. Secretion: Procollagen molecules secreted from Golgi apparatus
7. Propeptide cleavage: Extracellular ADAMTS proteases remove N- and C-propeptides
8. Fibrillogenesis: Collagen monomers assemble into quarter-staggered arrays
9. Cross-linking: Lysyl oxidase creates covalent cross-links

Consequences of Mutations:

• Quantitative defects (Type I OI): Reduced collagen quantity, but normal structure → osteopenia
• Qualitative defects (Types II-IV): Abnormal collagen incorporation → disrupted fibrillogenesis, abnormal cross-linking, endoplasmic reticulum stress, osteoblast apoptosis
• Post-translational modification defects: Over-modification of collagen, abnormal mineral deposition [15]

Bone Microarchitecture

Studies using high-resolution peripheral quantitative computed tomography (HR-pQCT) demonstrate: [16]

• Reduced cortical thickness
• Increased cortical porosity
• Decreased trabecular number and thickness
• Abnormal trabecular architecture
• Reduced bone mineral density (BMD)

Cellular Abnormalities

• Osteoblasts: Reduced numbers, impaired differentiation, increased apoptosis
• Osteoclasts: Variable reports; bisphosphonates target osteoclastic bone resorption
• Bone matrix: Abnormal collagen cross-linking, altered mineral-to-matrix ratio [17]

Extraskeletal Manifestations - Pathophysiology

Type I collagen is distributed throughout connective tissues:

---

4. Clinical Presentation

Sillence Classification (1979)

The Sillence classification remains the most widely used clinical typing system, despite recognition of additional genetic subtypes. [2]

Type V and beyond: Subsequently described types (V–XIX) based on specific genetic mutations or unique clinical features (e.g., Type V with hyperplastic callus, Type VI with fish-scale bone lamellation). [18]

Clinical Features by System

Skeletal Manifestations

Fractures:

• Frequency: Highly variable; Type I may have 10–20 lifetime fractures, Type III may have hundreds
• Sites: Long bones (femur, tibia, humerus) most common; vertebral compression fractures frequent
• Age pattern:
  • "Type I: Peak in toddler years, decrease after puberty"
  • "Type III: Continuous throughout life, including adulthood"
• Triggering trauma: Minimal or absent; may fracture during nappy changes, routine care [19]

Skeletal Deformities:

• Long bone bowing: Anterior-lateral femoral bowing, anterior tibial bowing
• Vertebral compression fractures: Kyphoscoliosis, loss of height
• Pectus deformity: Carinatum or excavatum
• Protrusio acetabuli: Medial migration of femoral head into pelvis [20]

Skull and Craniofacial:

• Wormian bones: Intrasutural ossicles on skull radiographs (> 10 bones, > 6mm size suggestive) [21]
• Frontal bossing: Prominent forehead
• Triangular facies: Broad forehead tapering to small chin
• Basilar invagination: Cranial settling, odontoid process migrates superiorly, risk of brainstem compression (especially Type III) [22]

Ocular Features

• Blue/grey sclerae: Pathognomonic in Type I; scleral thickness ~50% of normal; colour fades with age in Type III
• Arcus senilis: Premature appearance
• Keratoconus: Rare association
• Retinal detachment: Rare

Dental Manifestations

Dentinogenesis Imperfecta (DI):

• Occurs in ~50% overall (Type IB and Type IVB subclassifications)
• Clinical features: Opalescent, grey-brown or blue-grey teeth; enamel chips easily; rapid wear; bulbous crowns; obliterated pulp chambers
• Radiographic features: Bulbous crowns, cervical constriction, short roots, pulp obliteration [23]

Auditory System

• Prevalence: 50% by adulthood in Type I; less common in other types
• Type: Conductive (stapes fixation, ossicular chain abnormalities), sensorineural, or mixed
• Onset: Typically 20s–30s, but can occur in adolescence
• Mechanism: Microfractures of otic capsule, otosclerosis-like changes [24]

Cardiovascular

• Valvular disease: Mitral valve prolapse, aortic regurgitation (10–15% of Type I adults)
• Aortic root dilatation: Rare, severe types
• Arrhythmias: Rare association [25]

Respiratory

• Restrictive lung disease: Thoracic cage deformity, scoliosis reduce lung capacity
• Type III: Significant contributor to mortality
• Recurrent pneumonias: Impaired cough effectiveness [26]

Neurological

• Basilar invagination complications: Headache, lower cranial nerve palsies, cerebellar signs, quadriparesis
• Hydrocephalus: Rare, associated with severe basilar invagination
• Spinal cord compression: Vertebral fractures, atlantoaxial instability

Other Features

• Joint hypermobility: Ligamentous laxity in ~50%
• Easy bruising: Thin skin, vascular fragility
• Hernias: Inguinal, umbilical
• Excessive sweating: Thermoregulatory dysfunction
• Constipation: Common, especially in immobile children

Age-Specific Presentations

Prenatal

• Ultrasound findings (Type II, severe Type III):
  • Multiple fractures
  • Shortened, bowed long bones
  • Reduced bone mineralisation (hypoechoic bones)
  • Beaded ribs
  • Small thorax
  • Polyhydramnios [27]

Neonatal

• Type II (lethal):
  • Extreme bone fragility, multiple fractures
  • Soft skull (caput membranaceum)
  • Dark blue sclerae
  • Respiratory failure (thoracic cage hypoplasia)
  • Death within hours to weeks
• Type III:
  • Multiple fractures at birth
  • Shortened limbs
  • Triangular facies, blue sclerae
  • Respiratory distress

Infancy and Childhood

• Type I:
  • First fracture typically 1–3 years (when walking starts)
  • Recurrent fractures with minimal trauma
  • Blue sclerae persist
  • Normal development and intelligence
• Type III:
  • Progressive deformity
  • Severe short stature
  • Delayed motor milestones
  • Wheelchair dependence by school age
• Type IV:
  • Intermediate presentations
  • Fractures mainly in childhood
  • Moderate short stature

Adolescence

• Type I: Fracture frequency typically decreases after puberty
• Type III: Continued fractures, progressive scoliosis
• All types: Psychosocial challenges (body image, peer relationships, independence)

---

5. Clinical Examination

Systematic Approach

General Inspection

• Growth parameters: Height, weight, head circumference (plot on growth charts)
• Mobility: Wheelchair, walking aids, independent ambulation
• Skeletal deformities: Limb alignment, spine curvature
• Overall appearance: Triangular facies, blue sclerae visible from distance

Skull and Face

Eyes

• Sclerae: Blue (Type I), grey-blue (young Type III), white (Type IV)
• Cornea: Clear (check for keratoconus if suspected)
• Pupils: Equal and reactive
• Movements: Full range (check for nystagmus if basilar invagination suspected)

Ears

• Otoscopy: Tympanic membrane appearance
• Hearing assessment: Whisper test, tuning fork tests (Rinne, Weber), formal audiometry referral
• Developmental hearing screen: Essential in all children with OI

Cardiovascular

• Heart sounds: Murmurs (mitral regurgitation, aortic regurgitation)
• Pulses: Character and symmetry
• Blood pressure: Age-appropriate cuff

Respiratory

• Chest shape: Pectus carinatum/excavatum, barrel chest
• Respiratory rate: May be elevated if restrictive lung disease
• Auscultation: Air entry, added sounds
• Oxygen saturations: If respiratory concerns

Abdominal

• Inspection: Distension, hernias (umbilical, inguinal)
• Palpation: Organomegaly (usually absent)
• Hernias: Palpable, reducible

Musculoskeletal

Spine:

• Inspection: Kyphosis, scoliosis, gibbus
• Palpation: Vertebral step-offs, tenderness
• Range of movement: Flexion, extension, lateral flexion, rotation
• Neurology: If deformity significant or symptoms present

Limbs:

Skin

• Colour: Pallor, cyanosis
• Texture: Thin, translucent
• Bruising: Location, pattern, age of bruises (distinguish from non-accidental injury)
• Scars: Surgical, fracture-related

Neurological

• Cranial nerves: Particularly IX–XII if basilar invagination suspected
• Tone: Upper and lower limbs
• Power: MRC grading
• Reflexes: Symmetry, pathological reflexes (Babinski)
• Coordination: Finger-nose, heel-shin
• Gait: If ambulant

Examination Pearls

• Blue sclerae are not pathognomonic: Also seen in Ehlers-Danlos syndrome, Marfan syndrome, normal infants (less than 1 year)
• Wormian bones: Specificity increases with > 10 bones, each > 6mm
• Distinguish DI from other causes: Amelogenesis imperfecta affects enamel (not dentin)
• Hypermobility: Check Beighton score (joint hypermobility is supportive but not diagnostic)
• Leg length discrepancy: Common after fractures; assess for blocks/shoe raises

---

6. Differential Diagnosis

Critical Differentials

Non-Accidental Injury (NAI)

Distinguishing OI from NAI is a critical clinical challenge. [28]

Red flags for NAI (even in child with known OI):

• Posterior rib fractures (rare in OI)
• Classic metaphyseal lesions (bucket-handle, corner fractures)
• Retinal haemorrhages
• Subdural haemorrhages
• Pattern bruising (handprints, implement shapes)
• Burns with clear demarcation

Critical principle: OI and NAI are not mutually exclusive. Children with disabilities, including OI, are at higher risk of abuse. [29]

Other Metabolic Bone Diseases

Connective Tissue Disorders

Other Genetic Syndromes

• Cole-Carpenter syndrome: OI-like features + craniosynostosis, hydrocephalus, ocular proptosis; P4HB mutations
• Hajdu-Cheney syndrome: Acro-osteolysis, short stature, fractures, craniofacial anomalies; NOTCH2 mutations
• Caffey disease (infantile cortical hyperostosis): Periosteal new bone formation, soft tissue swelling, irritability; self-limiting

---

7. Investigations

Initial Diagnostic Workup

Radiography

Skeletal survey (essential in suspected OI):

Fracture healing: Often exuberant callus formation, especially Type V (hyperplastic callus) [30]

Bone Mineral Density (BMD)

• Modality: Dual-energy X-ray absorptiometry (DEXA)
• Findings: Low BMD (Z-score typically < -2.0 in untreated OI)
• Limitations: Z-scores less reliable in children with growth/size abnormalities; affected by vertebral compression fractures
• Role: Baseline assessment, monitoring treatment response (bisphosphonates increase BMD) [31]

Laboratory Investigations

Routine biochemistry (usually normal in OI):

Other markers:

• Bone turnover markers (P1NP, CTX): May be elevated; useful for monitoring bisphosphonate response
• Urinary calcium/creatinine ratio: Assess for hypercalciuria (bisphosphonate side effect)
• Renal function: Baseline before bisphosphonates

Advanced/Confirmatory Investigations

Genetic Testing

Gold standard for definitive diagnosis. [32]

Mutation types detected:

• Point mutations (missense, nonsense)
• Splice site mutations
• Small insertions/deletions
• Large deletions/duplications (MLPA or array CGH may be needed)

Interpretation:

• Pathogenic variants confirm diagnosis
• Variants of uncertain significance (VUS) require family studies, functional analysis
• No mutation identified: Does not exclude OI; consider mosaicism, deep intronic variants, or novel genes

Collagen Biochemical Analysis (Historical)

• Method: Cultured skin fibroblasts analysed for collagen synthesis, structure, post-translational modification
• Current use: Largely replaced by genetic testing; occasionally useful if genetic testing ambiguous
• Findings: Abnormal collagen migration on gel electrophoresis, reduced quantity, abnormal structure [33]

Imaging for Complications

Audiometry

• Initial: By 5 years of age, then periodically (e.g., every 2–3 years)
• Modality: Pure tone audiometry, tympanometry, otoacoustic emissions
• Findings: Conductive, sensorineural, or mixed hearing loss [24]

Exam Detail: ### Interpretation Pearls

Wormian bones:

• Sensitivity ~70–80% in OI
• Specificity: Also seen in cleidocranial dysplasia, hypophosphatasia, hypothyroidism, rickets, Menkes disease, pyknodysostosis
• Key: > 10 bones, each > 6mm, increases specificity

DEXA Z-scores in children:

• Must be size-adjusted (height-for-age Z-score)
• Artefacts: Vertebral compression fractures spuriously lower BMD; scoliosis affects accuracy
• Serial measurements more useful than single value

Genetic counselling:

• Autosomal dominant: 50% recurrence risk for affected parent
• De novo mutation (common in Type II): Low recurrence risk (~1–2% due to germline mosaicism)
• Autosomal recessive: 25% recurrence risk in carrier parents
• Prenatal diagnosis: Chorionic villus sampling (CVS) or amniocentesis for at-risk pregnancies

---

8. Classification & Severity Assessment

Sillence Classification (1979) – Detailed

Type I (Mild, Non-Deforming)

• Genetics: COL1A1 null alleles (haploinsufficiency)
• Fracture frequency: ~10–20 lifetime fractures; decrease post-puberty
• Prognosis: Normal lifespan, good function

Type II (Perinatal Lethal)

• Genetics: COL1A1/COL1A2 structural mutations (glycine substitutions)
• Features: Multiple in utero fractures, soft skull, dark blue sclerae, severe respiratory failure
• Management: Palliative care discussions

Type III (Severe, Progressive Deforming)

• Sclerae: Blue at birth, lighten to grey then white with age
• DI: Common
• Features:
  • Multiple fractures at birth
  • Progressive long bone and spinal deformity
  • Severe short stature (often less than 3rd centile)
  • Wheelchair-dependent by adolescence
  • Basilar invagination (20–30%)
  • Restrictive lung disease
• Genetics: COL1A1/COL1A2 structural mutations; some autosomal recessive forms
• Prognosis: Reduced life expectancy (respiratory complications); significant functional impairment

Type IV (Moderate, Variable Deformity)

• Genetics: COL1A1/COL1A2 structural mutations
• Fracture frequency: Mainly childhood and adolescence
• Prognosis: Near-normal lifespan with appropriate management; variable function

Extended Classification (Types V–XIX+)

Defined by specific genetic mutations or unique histological/radiological features. [18]

Examples:

• Type V: Hyperplastic callus formation, calcification of interosseous membranes; IFITM5 mutations
• Type VI: Fish-scale bone lamellation on histology; SERPINF1 mutations
• Type VII: Rhizomelic short stature, coxa vara; recessive; CRTAP mutations
• Type VIII: Severe growth deficiency, extreme skeletal undermineralisation; LEPRE1 mutations

Functional Severity Grading

Van Dijk Classification (Functional): [34]

---

9. Management

Principles of Care

OI management is lifelong, multidisciplinary, and individualised. Goals: [35]

1. Reduce fracture frequency and pain
2. Optimise bone health
3. Prevent and manage deformity
4. Maximise mobility and function
5. Address extraskeletal complications
6. Support psychological and social well-being

Acute Fracture Management

Initial assessment:

• History: Mechanism (often minor/absent trauma)
• Examination: Deformity, neurovascular status
• Imaging: X-ray (two views)

Treatment:

Principles:

• Minimal immobilisation: Prolonged immobilisation worsens osteoporosis
• Early mobilisation: Physiotherapy start within days
• Avoid traction: Can cause additional fractures
• Analgesia: Paracetamol, ibuprofen; opiates if severe pain

Medical Management

Bisphosphonates (Mainstay)

Mechanism: Inhibit osteoclast-mediated bone resorption; increase BMD; reduce fracture risk. [36,37]

Indications:

• Recurrent fractures (≥2 long bone fractures per year)
• Vertebral compression fractures
• Chronic bone pain
• Low BMD
• Type III/IV usually require; Type I variable

Agents:

Dosing (Pamidronate):

• Initial cycle: Split dose over 3 consecutive days (e.g., 0.25 mg/kg/day × 3 days = 0.75 mg/kg total)
• Subsequent cycles: Single infusion every 2–4 months
• Duration: At least 2–4 years; often continued until skeletal maturity

Monitoring:

• Pre-treatment: Calcium, phosphate, ALP, renal function, vitamin D
• Post-infusion: Calcium, phosphate (risk of hypocalcaemia)
• Annual: DEXA scan, vertebral imaging, renal function
• Urine calcium: Periodically (risk of hypercalciuria)

Adverse effects:

• Acute phase reaction (first infusion): Fever, myalgia, bone pain (50–70%); prevent with paracetamol/ibuprofen
• Hypocalcaemia: Especially if vitamin D deficient; supplement calcium/vitamin D
• Hypercalciuria: Monitor; ensure adequate hydration
• Osteonecrosis of jaw: Rare in children; maintain dental hygiene
• Atypical femoral fractures: Very rare in paediatric use; theoretical concern with prolonged use [38]

Efficacy:

• ↑ BMD by 30–60% over 2–4 years
• ↓ Fracture rate by 20–50%
• ↓ Bone pain
• Improved vertebral shape (reduced further compression)
• Quality of life improvement [36,37]

Limitations:

• Does not cure OI
• Fractures still occur (reduces frequency, not eliminates)
• Optimal duration unknown
• Long-term safety (> 10 years) uncertain

Calcium and Vitamin D Supplementation

• Calcium: 500–1000 mg/day (dietary + supplement)
• Vitamin D: 400–800 IU/day; aim serum 25-OH vitamin D > 50 nmol/L (> 20 ng/mL)
• Rationale: Prevent secondary hyperparathyroidism; support bone mineralisation; reduce bisphosphonate-induced hypocalcaemia [39]

Emerging Therapies

Surgical Management

Intramedullary Rodding

Indications:

• Recurrent fractures same bone (≥2–3)
• Progressive bowing deformity
• Non-union or delayed union
• Prophylactic (severe types, e.g., Type III femur/tibia)

Rod Types:

Technique (e.g., femur):

1. Entry point: Greater trochanter (antegrade) or distal femur (retrograde)
2. Ream canal gently (bones fragile)
3. Insert rod spanning length of bone
4. Fix proximally and distally (screws, wires, or T-pieces)
5. Correct deformity (may require osteotomies)

Outcomes:

• ↓ Fracture frequency in rodded bone
• ↑ Mobility, weight-bearing
• ↓ Deformity progression
• Improved quality of life [44]

Complications:

• Intraoperative fractures
• Rod migration (10–30%)
• Mechanical failure (telescoping rod malfunction)
• Infection (less than 5%)
• Non-union at osteotomy site
• Requirement for revision surgery (growth, complications)

Spinal Surgery

Indications:

• Progressive scoliosis (Cobb angle > 40–50°)
• Respiratory compromise
• Pain
• Sitting balance issues

Procedures:

• Growing rods: For young children (less than 10 years); lengthened periodically
• Definitive fusion: For older children/adolescents; posterior spinal fusion with instrumentation
• Challenges: Osteoporotic vertebrae; poor screw purchase; high complication rates [45]

Basilar Invagination Surgery

Indications:

• Neurological symptoms (cranial nerve palsies, cerebellar signs, quadriparesis)
• Progressive cranial settling
• Brainstem compression on MRI

Procedures:

• Posterior decompression (suboccipital craniectomy, C1 laminectomy)
• Occipitocervical fusion
• Risks: High morbidity; CSF leak; vertebral artery injury; require specialist neurosurgical centres [22]

Other Surgical Procedures

• Osteotomies: Correct rotational/angular deformity
• Epiphysiodesis: Leg length discrepancy
• Joint replacement: Protrusio acetabuli (total hip replacement in adults)
• Dental: Crowns, restorations for DI

Multidisciplinary Team (MDT)

Rehabilitation and Supportive Care

Physiotherapy

Goals:

• Maintain/improve muscle strength
• Preserve joint range of motion
• Promote safe mobility
• Prevent contractures

Interventions:

• Hydrotherapy: Low-impact, weight-supported exercise
• Gentle strengthening: Resistance bands, low weights
• Balance training: Reduce fall risk
• Gait training: Walking aids, orthoses
• Breathing exercises: Respiratory muscle training [46]

Precautions:

• Avoid high-impact activities
• Monitor for pain, fracture risk
• Individualised programmes

Activity and Lifestyle

Recommendations:

• Encourage activity: Sedentary lifestyle worsens osteoporosis
• Safe activities: Swimming, hydrotherapy, cycling, wheelchair sports
• Avoid: Contact sports, trampolining, high-impact activities
• School: Individual healthcare plans; PE adaptations; lift access; extra time for mobility [47]

Psychosocial Support

• Peer support: Contact with other families (e.g., Brittle Bone Society)
• Body image: Adolescents particularly vulnerable
• Independence: Adaptive equipment, home modifications
• Transition to adult services: Planned, gradual

Special Considerations

Pregnancy and Reproductive Counselling

• Genetic counselling: Recurrence risk, prenatal diagnosis options
• Pregnancy in women with OI:
  • Increased fracture risk (especially third trimester, postpartum)
  • Pelvic deformity may necessitate caesarean section
  • Anaesthetic challenges (spinal deformity, cervical instability)
  • Fetal risk if partner also affected or if autosomal recessive [48]

Anaesthesia Considerations

• Airway: Potential difficult intubation (cervical spine instability, basilar invagination)
• Positioning: Careful (fracture risk from patient movement/positioning)
• Regional anaesthesia: Challenging (spinal deformity)
• Temperature regulation: Hypothermia risk (thin skin, poor thermoregulation) [49]

---

10. Complications

Short-Term Complications

Long-Term Complications

Skeletal

• Progressive deformity: Bowing, scoliosis, kyphosis → functional impairment, pain
• Short stature: Especially Type III (adult height often less than 120 cm)
• Osteoarthritis: Secondary to joint incongruity, deformity
• Protrusio acetabuli: Hip pain, restricted ROM, premature arthritis [20]

Neurological

• Basilar invagination:
  • "Prevalence: 5–10% overall; up to 30% Type III"
  • "Symptoms: Headache, lower cranial nerve palsies (IX, X, XI, XII), cerebellar signs, upper motor neuron signs, sleep apnoea"
  • "Complications: Sudden death (brainstem compression), quadriplegia [22]"
• Spinal cord compression: Vertebral collapse, spinal deformity
• Hydrocephalus: Secondary to basilar invagination

Cardiovascular

• Valvular heart disease: Mitral valve prolapse (20–30% Type I adults), aortic regurgitation (10–15%)
• Aortic root dilatation: Rare, severe types; risk of dissection
• Sudden cardiac death: Very rare; conduction abnormalities [25]

Respiratory

• Restrictive lung disease:
  • "Prevalence: Type III 50–70%; Type IV 20–30%"
  • "Causes: Thoracic cage deformity (pectus, scoliosis), rib fractures, kyphosis"
  • "Consequences: Reduced lung capacity, recurrent pneumonias, respiratory failure"
  • Leading cause of death in Type III [26]

Auditory

• Hearing loss:
  • "Prevalence: 50% Type I by adulthood; less common other types"
  • "Onset: Typically 20s–30s, can be adolescent"
  • "Type: Conductive, sensorineural, or mixed"
  • "Impact: Social isolation, educational difficulties [24]"

Dental

• Dentinogenesis imperfecta complications:
  • Rapid tooth wear
  • Tooth fracture
  • Dental abscesses
  • Early tooth loss
  • Requires extensive restorative work [23]

Renal

• Nephrocalcinosis/kidney stones: Associated with hypercalciuria (bisphosphonates, immobilisation)

Psychosocial

• Chronic pain: Fractures, deformity, arthritis
• Depression and anxiety: Body image, functional limitations, social isolation
• Reduced quality of life: Mobility restrictions, dependence
• Educational/vocational challenges: School absences, physical limitations [50]

---

11. Prognosis & Outcomes

Type-Specific Prognosis

Factors Affecting Prognosis

Positive prognostic factors:

• Type I genotype
• Early bisphosphonate therapy
• Access to specialist MDT care
• Proactive surgical management (rodding)
• Absence of basilar invagination
• Preserved respiratory function
• Family and social support [51]

Negative prognostic factors:

• Type III genotype
• Severe baseline deformity
• Basilar invagination
• Restrictive lung disease (FVC less than 50% predicted)
• Recurrent respiratory infections
• Lack of access to specialist care

Modern Outcomes

Impact of bisphosphonates and modern management: [36,37,52]

• ↓ Fracture frequency by 20–50%
• ↑ Mobility and function
• ↓ Chronic pain
• ↑ Quality of life scores
• ↑ School attendance
• Many Type IV (and some Type III) children now ambulatory who would historically have been wheelchair-bound

Adult outcomes:

• Type I: Normal lifespan, employment, family life
• Type III: Reduced lifespan (respiratory complications); many achieve education, employment, independent living with support
• Type IV: Near-normal lifespan; most independent

Mortality

• Type II: 100% perinatal/early infant mortality
• Type III: Increased mortality; respiratory failure is leading cause
• Type I/IV: Near-normal life expectancy with modern care [53]

---

12. Prevention & Screening

Primary Prevention

• Genetic counselling:
  • Families with affected individuals
  • Recurrence risk assessment
  • Prenatal diagnosis options (CVS, amniocentesis)
  • Preimplantation genetic diagnosis (PGD) for known mutations [54]

Secondary Prevention (Fracture Risk Reduction)

• Bisphosphonate therapy: Mainstay
• Optimise nutrition: Adequate calcium, vitamin D, protein
• Safe environment:
  • Home modifications (remove trip hazards, soft flooring)
  • Protective equipment (helmets for toddlers, knee/elbow pads)
  • Appropriate car seats, wheelchairs
• Education: Family, school, caregivers on safe handling

Tertiary Prevention (Complication Screening)

---

13. Key Guidelines & Evidence

International Guidelines

Landmark Evidence

1. Sillence et al. (1979): Clinical classification of OI into Types I–IV [2]
2. Glorieux et al. (1998): First RCT of IV pamidronate in children with severe OI; demonstrated ↑ BMD, ↓ fractures [57]
3. Rauch et al. (2003): IV pamidronate improves vertebral shape and reduces fractures in children with OI [58]
4. Ward et al. (2011): Cochrane review: Bisphosphonates increase BMD in OI; fracture reduction data limited [59]
5. Dwan et al. (2016): Cochrane update: Bisphosphonates ↑ BMD, ↓ fracture risk in children with OI [60]
6. Forlino & Marini (2016): Comprehensive review of OI genetics and pathophysiology [3]

---

14. Examination Focus

Common Exam Questions (MRCPCH, FRCS Tr&Orth)

Short Answer Questions (SAQs)

Q1: A 3-year-old child presents with a femoral fracture after a minor fall. Examination reveals blue sclerae. What is your differential diagnosis and initial investigations?

Model Answer: Differential diagnosis includes:

1. Osteogenesis Imperfecta (most likely): Blue sclerae highly suggestive; fracture from minimal trauma
2. Non-accidental injury: Must always consider; however, blue sclerae make OI more likely
3. Rickets: Can present with fractures, but blue sclerae unusual
4. Hypophosphatasia: Rickets-like features, but blue sclerae not typical

Initial investigations:

• X-rays: Fracture site (confirm diagnosis, exclude other injuries); skeletal survey (skull for Wormian bones, long bones for osteopenia, spine for vertebral fractures, ribs)
• Bloods: Calcium, phosphate, alkaline phosphatase, PTH, 25-OH vitamin D (exclude rickets, hypophosphatasia)
• Genetic testing: COL1A1/COL1A2 sequencing if OI suspected
• Safeguarding assessment: Detailed history, social review; involve paediatric team

Q2: Outline the medical and surgical management of a 7-year-old with Type III OI.

Model Answer: Type III OI is severe, progressive deforming OI requiring multidisciplinary management.

Medical:

• Bisphosphonates: IV pamidronate (0.75–1 mg/kg every 2–4 months) or zoledronate (0.025–0.05 mg/kg every 6–12 months); ↑ BMD, ↓ fracture frequency
• Calcium and vitamin D: Supplementation to support bone health
• Monitoring: DEXA annually, vertebral imaging, renal function, urine calcium

Surgical:

• Intramedullary rodding: Femur, tibia (recurrent fractures, bowing deformity); telescoping rods (Fassier-Duval) to accommodate growth
• Spinal surgery: If progressive scoliosis (Cobb > 40–50°); growing rods or fusion
• Basilar invagination surgery: If neurological symptoms (decompression, occipitocervical fusion)

Multidisciplinary:

• Physiotherapy (mobility, strengthening), occupational therapy (ADLs, equipment), orthotics (splints), audiology (hearing), dentistry (DI), psychology (coping), social work (school, benefits)

Q3: How do you differentiate OI from non-accidental injury?

Model Answer: Differentiation is critical but challenging; OI and NAI are not mutually exclusive.

Red flags for NAI even in known OI:

• Metaphyseal corner/bucket-handle fractures
• Posterior rib fractures
• Retinal haemorrhages
• Subdural haemorrhages

Action: If any concern, involve safeguarding team; detailed assessment.

Viva Questions

Viva Point: Opening statement for "Tell me about Osteogenesis Imperfecta":

"Osteogenesis Imperfecta is a heritable connective tissue disorder characterised by bone fragility due to defects in type I collagen. It affects approximately 1 in 10,000–20,000 live births. The classical forms result from mutations in COL1A1 or COL1A2 genes, inherited in an autosomal dominant pattern. Clinically, it ranges from mild (Type I) with blue sclerae and fractures in childhood, to perinatal lethal forms (Type II). Management is multidisciplinary, involving bisphosphonate therapy, surgical rodding for recurrent fractures, and comprehensive supportive care."

Key facts to mention:

1. Sillence classification: Types I–IV based on severity, sclerae colour, presence of DI
2. Genetics: 85–90% COL1A1/COL1A2; autosomal dominant (most); rarer recessive forms
3. Pathophysiology: Type I collagen defects → bone fragility, also affects sclera, dentin, ligaments, ossicles
4. Clinical: Fractures from minimal trauma, blue sclerae (Type I), DI, hearing loss, short stature, deformity
5. Differential: NAI critical to exclude; also rickets, hypophosphatasia
6. Investigations: Skeletal survey (Wormian bones, osteopenia), genetic testing (confirmatory), DEXA (BMD)
7. Management: Bisphosphonates (IV pamidronate/zoledronate; ↑ BMD, ↓ fractures); intramedullary rodding (telescoping rods); MDT
8. Evidence: Glorieux 1998, Rauch 2003 (pamidronate RCTs); Cochrane reviews confirm efficacy
9. Prognosis: Type I normal lifespan; Type III reduced (respiratory complications); modern care has transformed outcomes

Viva Question: "A neonate has multiple fractures detected on antenatal ultrasound. What is your differential and how would you manage?"

Model Answer: Multiple fractures in utero suggest severe skeletal dysplasia.

Differential diagnosis:

1. Osteogenesis Imperfecta Type II (perinatal lethal): Most likely
2. OI Type III (severe, progressive)
3. Hypophosphatasia (perinatal lethal form)
4. Achondrogenesis: Lethal skeletal dysplasia
5. Thanatophoric dysplasia: Short-limbed dwarfism, lethal

Investigations:

• Detailed ultrasound: Assess bone mineralisation, long bone length, thoracic cage (hypoplasia suggests poor prognosis), skull
• MRI: If ultrasound inconclusive
• Genetic testing:
  • Amniocentesis or fetal blood sampling for DNA analysis (COL1A1/COL1A2 sequencing)
  • Array CGH to exclude chromosomal abnormalities
• Parental X-rays: Assess for mild parental OI (Type I parents may have Type II child)

Management:

• Antenatal:
  • Multidisciplinary discussion (obstetrics, genetics, neonatology, palliative care)
  • Genetic counselling (prognosis, recurrence risk, parental wishes)
  • "If Type II likely: Discuss prognosis (perinatal lethal); consider termination if legal/acceptable; if continuing, plan palliative care"
  • "If Type III possible: Plan delivery in tertiary centre with neonatal support"
• Delivery: Caesarean section may reduce fracture risk
• Postnatal:
  • "If Type II: Palliative care, family support"
  • "If Type III: Initiate supportive care, bisphosphonates, MDT involvement"

Key point: Sensitive communication; support family decision-making; involve palliative care early if poor prognosis.

Common Mistakes (Avoid to Pass)

❌ Mistake 1: Assuming blue sclerae are diagnostic of OI

• Blue sclerae also seen in Ehlers-Danlos, Marfan, normal infants
• Diagnosis requires genetic testing or supportive features (Wormian bones, family history, osteopenia)

❌ Mistake 2: Missing NAI in child with OI

• OI does not exclude NAI; disabled children at higher abuse risk
• Metaphyseal corner fractures, posterior rib fractures are red flags

❌ Mistake 3: Prolonged immobilisation after fractures

• Worsens osteoporosis
• Aim minimal immobilisation (2–3 weeks children), early mobilisation

❌ Mistake 4: Starting bisphosphonates without calcium/vitamin D

• Risk severe hypocalcaemia
• Always supplement calcium (500–1000 mg/day) and vitamin D (400–800 IU/day)

❌ Mistake 5: Confusing DI with other dental conditions

• DI: Affects dentin (opalescent, grey-brown, enamel chips, obliterated pulp)
• Amelogenesis imperfecta: Affects enamel only (hypoplastic/hypocalcified enamel, normal dentin)

❌ Mistake 6: Failing to screen for basilar invagination in Type III

• 20–30% prevalence in Type III
• Can present insidiously; annual neurology review essential

❌ Mistake 7: Not considering hearing loss

• 50% Type I by adulthood
• Baseline audiometry by age 5, then every 2–3 years

---

15. Patient / Layperson Explanation

What is Osteogenesis Imperfecta?

Osteogenesis Imperfecta (OI), often called "brittle bone disease," is a genetic condition that affects how your child's body makes collagen—a protein that gives bones their strength. In OI, the collagen doesn't form properly, which makes bones more fragile and prone to breaking.

OI affects about 1 in every 10,000–20,000 babies born. It can range from very mild (a few fractures in childhood) to more severe (many fractures and other health issues).

What causes it?

OI is usually caused by a change (mutation) in genes called COL1A1 or COL1A2. These genes provide instructions for making collagen. The mutation can be:

• Inherited from a parent who also has OI
• New (de novo), meaning it happened for the first time in your child and wasn't inherited

What are the signs and symptoms?

Bones:

• Fractures (broken bones) that happen easily, sometimes from very gentle handling or minor bumps
• Bones may heal normally but sometimes become bent or bowed

Eyes:

• Blue or grey colour to the whites of the eyes (especially in milder types)

Teeth:

• Some children have weak, discoloured teeth that chip or wear down easily (called dentinogenesis imperfecta)

Hearing:

• Hearing loss can develop, usually in adulthood, but sometimes in teenagers

Height:

• Children with more severe types may be shorter than average

Other:

• Loose joints (hypermobility)
• Easy bruising

How is OI diagnosed?

Your doctor will:

1. Listen to your story: How and when fractures happened
2. Examine your child: Look for blue sclerae, check bones and joints, assess growth
3. X-rays: Look at bones to check for fractures, bone density, and special features (like extra small bones in the skull called "Wormian bones")
4. Blood tests: To rule out other conditions like rickets
5. Genetic test: A blood test to look for the gene mutation (this confirms the diagnosis)

How is OI treated?

There's no cure for OI, but treatment can help strengthen bones, reduce fractures, and improve quality of life.

Medications:

• Bisphosphonates: Special medications given as a drip into a vein (IV) every few months. They help make bones stronger and reduce fractures. Common ones are pamidronate and zoledronate.
• Calcium and vitamin D: Supplements to support bone health

Surgery:

• Rods in bones: If your child has repeated fractures in the same bone (like the thigh or shin), doctors can put a metal rod inside the bone to make it stronger and straighter. Some rods are "telescoping," meaning they can grow with your child.
• Spine surgery: If the spine curves severely (scoliosis), surgery may be needed

Physiotherapy:

• Exercises to keep muscles strong and joints flexible
• Hydrotherapy (water exercises) is often helpful because it's gentle on bones

Other support:

• Wheelchairs, walking aids, or orthotics (special shoes/braces) if needed
• Dental care for tooth problems
• Hearing tests and hearing aids if needed
• Psychological support for your child and family

What about fractures?

Fractures are treated like any broken bone:

• Pain relief (paracetamol, ibuprofen)
• A lightweight cast or splint to hold the bone in place while it heals
• Important: Keep the cast on for as short a time as possible (usually 2–3 weeks in children) and get your child moving again quickly. Resting too long can make bones weaker.

Will my child be able to walk and go to school?

Many children with OI can walk, go to school, and do many normal activities. It depends on the type:

• Mild OI (Type I): Most children walk independently, attend mainstream school, and have a normal lifespan
• Moderate OI (Type IV): Many children walk with aids (crutches, sticks) and attend school with some adaptations
• Severe OI (Type III): Children often use a wheelchair but can still go to school, use computers, and participate in adapted activities

Schools can make adjustments: lifts, extra time to move between classes, adapted PE.

What activities are safe?

• Encourage: Swimming, hydrotherapy, wheelchair sports, cycling (with care)
• Avoid: Contact sports (rugby, football), trampolining, high-impact activities

The key is to keep your child active (inactive bones get weaker) but safe.

Will OI affect my child's intelligence or development?

No. Children with OI have normal intelligence and development (unless there are rare complications affecting the brain).

What's the outlook?

• Mild OI: Fractures usually decrease after puberty. Normal lifespan and quality of life.
• More severe OI: Fractures may continue into adulthood. Modern treatments (bisphosphonates, surgery) have greatly improved outcomes. Many adults with OI have jobs, families, and fulfilling lives.

Is it my fault?

No. OI is a genetic condition. It's not caused by anything you did or didn't do during pregnancy.

Where can I get support?

• Brittle Bone Society (UK): www.brittlebone.org – Information, support groups, helpline
• Osteogenesis Imperfecta Foundation (International): www.oif.org – Resources, research updates, community
• Your hospital's OI specialist team: Nurses, physiotherapists, social workers

Questions to ask your doctor

1. What type of OI does my child have?
2. What treatments do you recommend?
3. How often will my child need bisphosphonate infusions?
4. When should we consider surgery?
5. What signs should I watch for (complications)?
6. How do we make home and school safe?
7. What's the plan for hearing and dental checks?
8. What about future children? (Genetic counselling)

Remember: You're not alone. Many families are living well with OI. With the right support, your child can thrive.

---

16. References

1. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164A(6):1470-1481. doi:10.1002/ajmg.a.36545

2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101-116. doi:10.1136/jmg.16.2.101

3. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657-1671. doi:10.1016/S0140-6736(15)00728-X

4. Engelbert RH, Gerver WJ, Breslau-Siderius LJ, et al. Spinal complications in osteogenesis imperfecta: 47 patients 1-16 years of age. Acta Orthop Scand. 1998;69(3):283-286. doi:10.3109/17453679808999052

5. Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B. 2003;12(2):77-87. doi:10.1097/01.bpb.0000049567.23935.b9

6. Steiner RD, Pepin M, Byers PH. Osteogenesis Imperfecta. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. University of Washington, Seattle; 1993-2023. PMID: 20301472

7. Chevrel G, Schott AM, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006;21(2):300-306. doi:10.1359/JBMR.051015

8. Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. doi:10.1038/nrdp.2017.52

9. Pollitt R, McMahon R, Nunn J, et al. Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV. Hum Mutat. 2006;27(7):716. doi:10.1002/humu.9430

10. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377-1385. doi:10.1016/S0140-6736(04)16051-0

11. Byers PH. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet. 1991;28(7):433-442. doi:10.1136/jmg.28.7.433

12. Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat. 2007;28(3):209-221. doi:10.1002/humu.20429

13. Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869-2892. doi:10.1002/ajmg.a.37365

14. Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. doi:10.1002/ajmg.a.61366

15. Willing MC, Deschenes SP, Slayton RL, Roberts EJ. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996;59(4):799-809. PMID: 8808594

16. Folkestad L, Hald JD, Canudas-Romo V, et al. Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res. 2016;31(12):2159-2166. doi:10.1002/jbmr.2895

17. Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int. 1999;64(3):185-190. doi:10.1007/s002239900600

18. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53(1):1-5. doi:10.1016/j.ejmg.2009.10.007

19. Steiner RD, Basel D. COL1A1/2 Osteogenesis Imperfecta. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. University of Washington, Seattle; 1993-2023. PMID: 20301472

20. Borer L, Pichon B, Schaller F, et al. Protrusio acetabuli in osteogenesis imperfecta. Clin Orthop Relat Res. 2008;466(11):2817-2822. doi:10.1007/s11999-008-0456-x

21. Cremin B, Goodman H, Spranger J, Beighton P. Wormian bones in osteogenesis imperfecta and other disorders. Skeletal Radiol. 1982;8(1):35-38. doi:10.1007/BF00361366

22. Sawin PD, Menezes AH. Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management. J Neurosurg. 1997;86(6):950-960. doi:10.3171/jns.1997.86.6.0950

23. Majorana A, Bardellini E, Brunelli PC, Lacaita M, Cazzolla AP, Favia G. Dentinogenesis imperfecta in children with osteogenesis imperfecta: a clinical and ultrastructural study. Int J Paediatr Dent. 2010;20(2):112-118. doi:10.1111/j.1365-263X.2009.01020.x

24. Pillion JP, Shapiro J. Audiological findings in osteogenesis imperfecta. J Am Acad Audiol. 2008;19(8):595-601. doi:10.3766/jaaa.19.8.3

25. Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular abnormalities in adults with osteogenesis imperfecta. Am Heart J. 2011;161(3):523-529. doi:10.1016/j.ahj.2010.11.022

26. Widmann RF, Bitan FD, Laplaza FJ, Burke SW, DiMaio MF, Schneider R. Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta. Spine (Phila Pa 1976). 1999;24(16):1673-1678. doi:10.1097/00007632-199908150-00008

27. Munoz C, Filly RA, Golbus MS. Osteogenesis imperfecta type II: prenatal sonographic diagnosis. Radiology. 1990;174(1):181-185. doi:10.1148/radiology.174.1.2403679

28. Ablin DS, Greenspan A, Reinhart MA, Grix A. Differentiation of child abuse from osteogenesis imperfecta. AJR Am J Roentgenol. 1990;154(5):1035-1046. doi:10.2214/ajr.154.5.2108540

29. Marlowe A, Pepin MG, Byers PH. Testing for osteogenesis imperfecta in cases of suspected non-accidental injury. J Med Genet. 2002;39(6):382-386. doi:10.1136/jmg.39.6.382

30. Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000;15(9):1650-1658. doi:10.1359/jbmr.2000.15.9.1650

31. Bianchi ML, Bishop NJ, Guañabens N, et al. Rare causes of osteoporosis. J Clin Endocrinol Metab. 2020;105(7):e2017-e2028. doi:10.1210/clinem/dgaa104

32. Lindahl K, Åström E, Rubin CJ, et al. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet. 2015;23(8):1042-1050. doi:10.1038/ejhg.2015.81

33. Bonadio J, Byers PH. Subtle structural alterations in the chains of type I procollagen produce osteogenesis imperfecta type II. Nature. 1985;316(6030):363-366. doi:10.1038/316363a0

34. Van Brussel M, Takken T, Uiterwaal CS, Pruijs HJ, Van der Net J, Helders PJ, Engelbert RH. Physical training in children with osteogenesis imperfecta. J Pediatr. 2008;152(1):111-116. doi:10.1016/j.jpeds.2007.06.029

35. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. doi:10.1002/14651858.CD005088.pub4

36. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947-952. doi:10.1056/NEJM199810013391402

37. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18(4):610-614. doi:10.1359/jbmr.2003.18.4.610

38. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23. doi:10.1002/jbmr.1998

39. Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. Pediatrics. 2014;134(4):e1229-e1243. doi:10.1542/peds.2014-2173

40. Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O. Two years' experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9:145. doi:10.1186/s13023-014-0145-1

41. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5(3):309-313. doi:10.1038/6529

42. Fassier F, Sardar Z, Aarabi M, et al. Results and complications of a surgical technique for correction of coxa vara in children with osteopenic bones. J Pediatr Orthop. 2008;28(8):799-805. doi:10.1097/BPO.0b013e31818e8569

43. Nicolaou N, Bowe JD, Wilkinson JM, Fernandes JA, Bell MJ. Use of the Sheffield telescopic intramedullary rod system for the management of osteogenesis imperfecta: clinical outcomes at an average follow-up of nineteen years. J Bone Joint Surg Am. 2011;93(21):1994-2000. doi:10.2106/JBJS.J.01600

44. Sofield HA, Millar EA. Fragmentation, realignment, and intramedullary rod fixation of deformities of the long bones in children: a ten-year appraisal. J Bone Joint Surg Am. 1959;41-A:1371-1391. PMID: 13849487

45. Yong-Hing K, MacEwen GD. Scoliosis associated with osteogenesis imperfecta. J Bone Joint Surg Br. 1982;64(1):36-43. doi:10.1302/0301-620X.64B1.7068715

46. Takken T, Terlingen HC, Helders PJ, Pruijs H, Van der Ent CK, Engelbert RH. Cardiopulmonary fitness and muscle strength in patients with osteogenesis imperfecta type I. J Pediatr. 2004;145(6):813-818. doi:10.1016/j.jpeds.2004.08.003

47. Hill CL, Baird WO, Walters SJ. Quality of life in children and adolescents with osteogenesis imperfecta: a qualitative interview based study. Health Qual Life Outcomes. 2014;12:54. doi:10.1186/1477-7525-12-54

48. Cubert R, Cheng EY, Mack S, Pepin MG, Byers PH. Osteogenesis imperfecta: mode of delivery and neonatal outcome. Obstet Gynecol. 2001;97(1):66-69. doi:10.1016/s0029-7844(00)01109-3

49. Porsborg P, Astrup G, Bendix K. Osteogenesis imperfecta and anaesthesia. Paediatr Anaesth. 1995;5(4):261-264. doi:10.1111/j.1460-9592.1995.tb00302.x

50. Wekre LL, Kjensli A, Aasand K, Falch JA, Eriksen EF. Health-related quality of life in adults with osteogenesis imperfecta. Disabil Rehabil. 2011;33(17-18):1682-1689. doi:10.3109/09638288.2010.541544

51. Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ. Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr. 2000;137(3):397-402. doi:10.1067/mpd.2000.107892

52. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006;39(4):901-906. doi:10.1016/j.bone.2006.04.004

53. McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta. J Clin Pathol. 1996;49(8):627-630. doi:10.1136/jcp.49.8.627

54. Pyott SM, Schwarze U, Christiansen HE, et al. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet. 2011;20(8):1595-1609. doi:10.1093/hmg/ddr037

55. Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18(1):126-130. doi:10.1359/jbmr.2003.18.1.126

56. Simm PJ, Biggin A, Zacharin MR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54(3):223-233. doi:10.1111/jpc.13768

57. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947-952. doi:10.1056/NEJM199810013391402

58. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18(4):610-614. doi:10.1359/jbmr.2003.18.4.610

59. Ward LM, Rauch F, Glorieux FH. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002;31(1):12-18. doi:10.1016/s8756-3282(02)00790-1

60. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. doi:10.1002/14651858.CD005088.pub4

---